Pasithea Therapeutics Says Positive PAS-004 Tablet Pharmacokinetic Data In Ongoing Phase 1/1B Trial In Adult NF1 Patients
Nov 21 (Reuters) - Pasithea Therapeutics Corp KTTA.O:
PASITHEA THERAPEUTICS ANNOUNCES POSITIVE PAS-004 TABLET PHARMACOKINETIC (PK) DATA IN ONGOING PHASE 1/1B TRIAL IN ADULT NF1 PATIENTS
PASITHEA THERAPEUTICS CORP - TABLET PK EXPOSURE INCREASES PROPORTIONALLY WITH DOSE
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.